Precipio (NASDAQ:PRPO) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Precipio (NASDAQ:PRPO) from a hold rating to a buy rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Precipio presently has a consensus rating of “Sell”.

Precipio Stock Performance

PRPO stock opened at $25.40 on Friday. The business has a 50 day simple moving average of $24.93 and a two-hundred day simple moving average of $22.91. The company has a market capitalization of $45.21 million, a price-to-earnings ratio of -101.60 and a beta of 1.19. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10. Precipio has a 1-year low of $3.90 and a 1-year high of $29.53.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings results on Monday, March 30th. The biotechnology company reported $0.34 earnings per share (EPS) for the quarter. The business had revenue of $6.70 million for the quarter. Precipio had a negative net margin of 1.51% and a negative return on equity of 2.89%.

Hedge Funds Weigh In On Precipio

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 789 shares during the period. Renaissance Technologies LLC increased its stake in shares of Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Precipio in the third quarter worth $194,000. Evernest Financial Advisors LLC purchased a new position in shares of Precipio during the third quarter worth $374,000. Finally, Topline Capital Management LLC purchased a new position in shares of Precipio during the third quarter worth $1,158,000. Institutional investors and hedge funds own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.